ARCT
Arcturus Therapeutics Holdings IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$233.64M
P/E Ratio
—
EPS
$-2.40
Beta
2.44
52W High
$24.17
52W Low
$5.85
50-Day MA
$7.40
200-Day MA
$11.47
Dividend Yield
—
Profit Margin
-80.20%
Forward P/E
2.48
PEG Ratio
—
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $82.03M |
| Gross Profit (TTM) | $-30.18M |
| EBITDA | $-73.23M |
| Operating Margin | -435.10% |
| Return on Equity | -28.90% |
| Return on Assets | -15.50% |
| Revenue/Share (TTM) | $3.00 |
| Book Value | $7.53 |
| Price-to-Book | 1.07 |
| Price-to-Sales (TTM) | 2.85 |
| EV/Revenue | 0.332 |
| EV/EBITDA | -25.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -68.40% |
| Shares Outstanding | $28.42M |
| Float | $26.28M |
| % Insiders | 7.53% |
| % Institutions | 78.49% |
Analyst Ratings
Consensus ($23.30 target)
2
Strong Buy7
Buy3
HoldData last updated: 4/7/2026